{"id":9439,"date":"2025-08-26T06:34:51","date_gmt":"2025-08-26T11:34:51","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9439"},"modified":"2025-09-02T06:25:04","modified_gmt":"2025-09-02T11:25:04","slug":"nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/","title":{"rendered":"Nanoscope anuncia datos innovadores del ensayo REMAIN de 3 a\u00f1os para pacientes con retinosis pigmentaria en el Congreso Euretina 2025 y la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad de Retina."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Las ponencias destacan la eficacia, la durabilidad y la seguridad de la plataforma de terapia optogen\u00e9tica MCO (opsina multicaracter\u00edstica) de Nanoscope.<\/i><\/h3>

\u00a0Los datos constituyen la base de la reciente presentaci\u00f3n continua de la solicitud de licencia de productos biol\u00f3gicos ante la FDA para la retinosis pigmentaria.<\/i><\/h3>

DALLAS<\/span><\/span>,\u00a026 de agosto de 2025<\/span><\/span>\u00a0\u2014\u00a0Nanoscope Therapeutics Inc.,<\/a><\/b>\u00a0una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de nuevas terapias independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual por degeneraci\u00f3n retiniana, presentar\u00e1 nuevos datos convincentes de su estudio de seguimiento a largo plazo RESTORE, REMAIN, en el\u00a0Congreso Euretina 2025<\/a>\u00a0y\u00a0Reuni\u00f3n cient\u00edfica anual de la Retina Society<\/a>. Las presentaciones resaltan los resultados positivos de eficacia y seguridad a las 152 semanas de MCO-010 (sonpiretigene isteparvovec), la principal terapia optogen\u00e9tica de la compa\u00f1\u00eda para la retinosis pigmentaria (RP). MCO-010, que se administra mediante una inyecci\u00f3n intrav\u00edtrea \u00fanica en el consultorio, es la primera y \u00fanica terapia en un ensayo cl\u00ednico aleatorizado y controlado que ha demostrado restaurar la visi\u00f3n en pacientes con RP que presentan una p\u00e9rdida visual grave.<\/p>

\u201cLa eficacia duradera y la tolerabilidad a largo plazo son importantes para los pacientes que sufren una p\u00e9rdida de visi\u00f3n progresiva e irreversible debido a la retinosis pigmentaria, y resaltan el potencial de MCO-010 para redefinir el est\u00e1ndar de atenci\u00f3n para estos pacientes\u201d, afirm\u00f3.\u00a0Dr.\u00a0Samarendra Mohanty<\/span>, Presidente y Director Cient\u00edfico de Nanoscope<\/a>. \u201cEn Nanoscope vivimos un momento emocionante, ya que estamos preparando MCO-010 para su comercializaci\u00f3n, un proceso que comenz\u00f3 con el reciente inicio de nuestra solicitud de licencia biol\u00f3gica (BLA) escalonada ante la FDA.\u201d<\/p>

A continuaci\u00f3n se detallan las presentaciones:<\/p>

Congreso Euretina 2025,\u00a0Par\u00eds, Francia<\/span>:<\/u><\/b><\/p>

T\u00edtulo:\u00a0 \u00a0<\/i><\/span><\/p><\/td>

RESTO: An\u00e1lisis extendido de 152 semanas del estudio RESTORE de la terapia optogen\u00e9tica MCO-010 para la retinosis pigmentaria.<\/span><\/p><\/td><\/tr>

T\u00edtulo de la sesi\u00f3n:<\/i><\/span><\/p><\/td>

Documento gratuito 11 \u2013 Enfermedades retinianas hereditarias<\/span><\/p><\/td><\/tr>

Fecha de la sesi\u00f3n:<\/i><\/span><\/p><\/td>

Viernes, 5 de septiembre<\/span><\/p><\/td><\/tr>

Tiempo de sesi\u00f3n:<\/i>\u00a0<\/span><\/p><\/td>

17:24 CET<\/span><\/p><\/td><\/tr>

Presentador:<\/i>\u00a0<\/span><\/p><\/td>

Jordi Mon\u00e9s, MD, PhD; Director, Instituto de la M\u00e1cula, Barcelona, Espa\u00f1a<\/span><\/p><\/td><\/tr><\/tbody><\/table><\/div><\/div><\/div>

Reuni\u00f3n Anual de la Sociedad de Retina 2025,\u00a0Chicago, Illinois<\/span>, EE.UU:<\/u><\/b><\/p>

T\u00edtulo:\u00a0 \u00a0<\/i><\/span><\/p><\/td>

RESTO: An\u00e1lisis extendido de 152 semanas del estudio RESTORE de terapia optogen\u00e9tica MCO-010 para la retinosis pigmentaria.<\/span><\/p><\/td><\/tr>

T\u00edtulo de la sesi\u00f3n:<\/i><\/span><\/p><\/td>

Enfermedades gen\u00e9ticas, distrofias, degeneraciones<\/span><\/p><\/td><\/tr>

Fecha de la sesi\u00f3n:<\/i><\/span><\/p><\/td>

Mi\u00e9rcoles, 10 de septiembre<\/span><\/p><\/td><\/tr>

Tiempo de sesi\u00f3n:<\/i>\u00a0<\/span><\/p><\/td>

15:44 CDT<\/span><\/p><\/td><\/tr>

Presentador:<\/i>\u00a0<\/span><\/p><\/td>

Christine Kay, MD; Vitreoretinal Associates, Directora de Investigaci\u00f3n Cl\u00ednica y Gen\u00e9tica Retiniana<\/span><\/p><\/td><\/tr><\/tbody><\/table><\/div><\/div><\/div>

Para obtener m\u00e1s informaci\u00f3n sobre MCO y Nanoscope Therapeutics, visite:\u00a0www.nanostherapeutics.com<\/a>.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica para restaurar la visi\u00f3n, aplicable a cualquier enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos de la fase RESTORE\u00a02b<\/span>\u00a0Ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, y la designaci\u00f3n de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en pacientes con atrofia geogr\u00e1fica (AG) comience a finales de 2025. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Terap\u00e9utica con nanoscopios
(817) 857-1186
PR@nanostherapeutics.com\u00a0<\/a><\/p>

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Talks highlight efficacy, durability, and safety of Nanoscope\u2019s MCO (multi-characteristic opsin) optogenetic therapy platform \u00a0Data forms the foundation for recent rolling Biologics License Application submission with the FDA for retinitis pigmentosa DALLAS,\u00a0Aug. 26, 2025\u00a0\u2014\u00a0Nanoscope Therapeutics Inc.,\u00a0a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment from […]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9439","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T11:34:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-02T11:25:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting\",\"datePublished\":\"2025-08-26T11:34:51+00:00\",\"dateModified\":\"2025-09-02T11:25:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/\"},\"wordCount\":516,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/\",\"name\":\"Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-08-26T11:34:51+00:00\",\"dateModified\":\"2025-09-02T11:25:04+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/26\\\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope anuncia datos revolucionarios del ensayo REMAIN de 3 a\u00f1os para pacientes con retinosis pigmentaria en el Congreso Euretina 2025 y la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad de Retina - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-08-26T11:34:51+00:00","article_modified_time":"2025-09-02T11:25:04+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting","datePublished":"2025-08-26T11:34:51+00:00","dateModified":"2025-09-02T11:25:04+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/"},"wordCount":516,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/","url":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/","name":"Nanoscope anuncia datos revolucionarios del ensayo REMAIN de 3 a\u00f1os para pacientes con retinosis pigmentaria en el Congreso Euretina 2025 y la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad de Retina - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-08-26T11:34:51+00:00","dateModified":"2025-09-02T11:25:04+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/26\/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9439"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9439\/revisions"}],"predecessor-version":[{"id":9446,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9439\/revisions\/9446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}